بدائل البحث:
significant attention » significant potential (توسيع البحث), significant reduction (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significant attention » significant potential (توسيع البحث), significant reduction (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
-
581
Image 4_Metformin attenuates alveolar bone destruction in mice with apical periodontitis and inhibits pro-inflammatory cytokine synthesis in lipopolysaccharide-stimulated RAW264.7...
منشور في 2025"…</p>Results<p>Metformin significantly reduced periapical bone destruction on postoperative days 21 and 28, and decreased the number of osteoclasts on the periapical alveolar bone on postoperative day 28. …"
-
582
Image 2_Metformin attenuates alveolar bone destruction in mice with apical periodontitis and inhibits pro-inflammatory cytokine synthesis in lipopolysaccharide-stimulated RAW264.7...
منشور في 2025"…</p>Results<p>Metformin significantly reduced periapical bone destruction on postoperative days 21 and 28, and decreased the number of osteoclasts on the periapical alveolar bone on postoperative day 28. …"
-
583
Table 4_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xls
منشور في 2025"…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …"
-
584
Table 1_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx
منشور في 2025"…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …"
-
585
Data Sheet 1_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.docx
منشور في 2025"…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …"
-
586
Table 6_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.xlsx
منشور في 2025"…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …"
-
587
Table 5_Therapeutic potential of luteolin in central precocious puberty: insights from a danazol-induced rat model.docx
منشور في 2025"…</p>Results<p>In the danazol-induced CPP model, luteolin treatment significantly decreased the abundances of Estradiol (E2), luteinizing hormone serum, and follicle-stimulating hormone in sera; reduced organ coefficients and ovarian and uterine wet weights; and delayed vaginal opening. …"
-
588
Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"
-
589
Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"
-
590
Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"
-
591
Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"
-
592
Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"
-
593
Image 4_Cornuside mitigates acute lung injury through suppression of NLRP3 inflammasome-mediated pyroptosis and activation of the Keap1-Nrf2 antioxidant response.tif
منشور في 2025"….), has garnered increasing attention for its bone-protective, neuroprotective, anti-inflammatory, and anti-diabetic properties, yet its effects on ALI remain unclear.…"
-
594
Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"
-
595
Supplementary file 1_Cornuside mitigates acute lung injury through suppression of NLRP3 inflammasome-mediated pyroptosis and activation of the Keap1-Nrf2 antioxidant response.docx
منشور في 2025"….), has garnered increasing attention for its bone-protective, neuroprotective, anti-inflammatory, and anti-diabetic properties, yet its effects on ALI remain unclear.…"
-
596
Image 1_Cornuside mitigates acute lung injury through suppression of NLRP3 inflammasome-mediated pyroptosis and activation of the Keap1-Nrf2 antioxidant response.tif
منشور في 2025"….), has garnered increasing attention for its bone-protective, neuroprotective, anti-inflammatory, and anti-diabetic properties, yet its effects on ALI remain unclear.…"
-
597
Image 2_Cornuside mitigates acute lung injury through suppression of NLRP3 inflammasome-mediated pyroptosis and activation of the Keap1-Nrf2 antioxidant response.tif
منشور في 2025"….), has garnered increasing attention for its bone-protective, neuroprotective, anti-inflammatory, and anti-diabetic properties, yet its effects on ALI remain unclear.…"
-
598
Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"
-
599
Image 3_Cornuside mitigates acute lung injury through suppression of NLRP3 inflammasome-mediated pyroptosis and activation of the Keap1-Nrf2 antioxidant response.tif
منشور في 2025"….), has garnered increasing attention for its bone-protective, neuroprotective, anti-inflammatory, and anti-diabetic properties, yet its effects on ALI remain unclear.…"
-
600
Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
منشور في 2025"…However, its higher incidence of AEs requires cautious attention.</p>Systematic review registration<p>https://www.crd.york.ac.uk/PROSPERO/view/CRD42024559146, identifier CRD42024559146.…"